Stocktoria

Acrivon Therapeutics, Inc. ACRV

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-11-15

Acrivon Therapeutics, Inc. statistics & valuation

Market cap$71.9M
P / B0.6×
Return on equity-69.2%
Return on capital-73.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20212022202320242025
Operating margin (%)
20212022202320242025
Return on equity (%)
-18.30% -49.80% -45.60% -69.20% 20212022202320242025
Shares outstanding
1.8M 21.9M 22.5M 33.8M 38.5M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-15.20% -17.20% -43.70% -41.00% -60.10% 20212022202320242025
Free cash flow margin (%)
20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$9.32 -$7.56 -$2.74 -$2.38 -$2.02 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Return on assets-60.1%-41.0%-43.7%-17.2%-15.2%
Return on equity-69.2%-45.6%-49.8%-18.3%68.2%
Current ratio7.6910.559.7520.2734.46

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.